Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Protocol: 
AAAR1107
Phase: 
I

Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination with Pembrolizumab for Patients with Advanced/Metastatic Solid Tumors or Lymphomas

The purpose of this study is to: • test the safety and tolerability of the research study drug MK-1454. • find the highest dose of MK-1454 that can be given alone or in combination with pembrolizumab with the least risk of serious side effects.

Are you Eligible? (Inclusion Criteria)

1. Be >= 18 years of age on day of signing informed consent.
2. Voluntarily agreed to participate by giving written informed consent. The
subject may also provide
consent for Future Biomedical Research. However, the subject may participate in
the main trial
without participating in Future Biomedical Research
3. Have stage III or stage IV disease that is not surgically resectable.
4.Have an ECOG Performance Status of 0 or 1.

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States